Get our guide to planning and executing an M&A communications strategy. Download Now

Westicke Partners

Close

Posts by Tom McDonald

Tom McDonald

Tom McDonald is a Partner/Managing Director and Head of Business Development. He is responsible for marketing the firm’s capabilities to potential new clients as well as the institutional investment community.

Form 8-K or Press Release: Know the Difference When You Disclose News

Posted on March 4th, 2021. Posted by

Form 8-k or Press Release

One of our clients, a recently public diagnostics company, settled an ongoing royalty dispute with a major pharmaceutical company. The settlement amount was significantly lower than what our client had accrued, resulting in nearly $750 thousand upside to their P&L in the upcoming quarter.

Continue Reading

Our Most-Read Investor Relations Posts of 2020

Posted on February 23rd, 2021. Posted by

Top 2020 Westwicke Content

No one would argue that 2020 was unique and challenging for almost every industry, including healthcare. The year forced both public and private companies to reconsider many aspects of how they do business and communicate with the investment community. As we all adapted and learned, our Westwicke blog covered a variety of investor relations topics, both pandemic related and not. Below are some of the most popular blog posts we published this year.

Continue Reading

Panel Discussion and Highlights from the Westwicke / ICR Conference 2021

Posted on January 27th, 2021. Posted by

Westwicke ICR Conference 2021

The 2021 Westwicke / ICR Conference went virtual this year — and like many in-person events suddenly turned remote, attendees found new and unexpected opportunities for connecting with each other. Namely, the ability, finally, to be in two meetings at once.

Continue Reading

What Will 2021 Look Like for Healthcare Companies? 4 Predictions

Posted on December 17th, 2020. Posted by

What Will 2021 Look Like for Healthcare Companies?

No one could have predicted the events of 2020. However, given the strength and evolution of the healthcare and biotech industry over the past 12 months, the team at Westwicke has some ideas about how the upcoming year may unfold. Below, we provide insight into what the new year may bring.

Continue Reading

10 Disclosure Guidelines for Clinical Trial Data and Milestones

Posted on October 21st, 2020. Posted by

As life science and medical device companies seek regulatory approval for their products, they will likely encounter difficult disclosure decisions around clinical and regulatory events. Clinical trial data and milestones can present great opportunities as well as significant challenges.

Continue Reading

Things to Know About SPAC Transactions

Posted on September 25th, 2020. Posted by

Info About SPAC Transactions

Over the past several months, interest in special purpose acquisition companies (SPACs) has grown exponentially. SPAC transactions serve as an alternative to traditional IPOs, and while they have existed for many years, they are currently experiencing a resurgence within several industries.

Continue Reading

6 Commonly Asked Questions (and Answers) About Quiet Periods

Posted on September 9th, 2020. Posted by

Commonly Asked Questions About Quiet Periods

Public healthcare companies often question the best course of action during quiet periods — those stretches of time during which they should limit their interaction with Wall Street due to their knowledge of material and timely information that has not yet been disclosed. Specifically, management teams struggle to figure out what the quiet period means for their investor relations (IR) efforts.

Continue Reading

The Virtual IPO: How IPOs Are Changing

Posted on August 26th, 2020. Posted by

Expert Advice on IPOs

According to some experts, the past several months have created more change in the IPO market than the last 25 to 30 years. In the recent webinar hosted by ICR Capital and Davis Polk, those experts discussed what they’ve seen in the IPO market recently, changes to standard IPO processes, and what’s to come for IPOs during the remainder of the year.

Continue Reading

Form 8-K vs. Press Release: What’s the Difference?

Posted on August 19th, 2020. Posted by

Form 8-K vs. Press Release

There are many things public companies must consider when disseminating news. What is the most appropriate vehicle to disclose news to investors? In some instances, you will need to file a Form 8-K, the disclosure from the Security and Exchange Commission (SEC). Sometimes, the news will necessitate issuing a press release. And sometimes, you will file both.

Continue Reading

Biotech IPOs: What to Expect in the Second Half of 2020

Posted on August 6th, 2020. Posted by

Biotech IPOs

For much of the first half of 2020, the coronavirus pandemic ground most business to a halt. Biotech innovation, however, has continued in full force. Even during the turbulent first few months of the year, biotech companies have moved forward with successful IPOs.

The pandemic isn’t over, however, and cases continue to rise in parts of the U.S. What will that mean for IPOs in the second half of the year?

Continue Reading

1 2 3 11

Planning an investor day?

Investor days — whether virtual on in-person — should play a key role in your investor relations strategy. Use our new eBook, How to Host a Successful Investor Day, to plan and coordinate your next event.

Our Locations